The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Trial finds weight loss drug taken monthly helps people lose 20% of body weight - The new drug may rival other weight loss ...

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...

New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...